Description
Market Report Coverage – Epigenetics Market
Market Segmentation
• Products (Consumables, Instruments, Software)
• Mechanism (DNA Methylation, Histone Modification, RNA Modification, and Others)
• Application (Oncology, Cardiovascular Diseases, Immunology, Metabolic Diseases, and Others)
• Technology (Polymerase Chain Reaction (PCR), Sequencing, Microarray, and Other Technologies (MS, Flow Cytometry))
• End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations (CROs), and Other End Users)
Regional Segmentation
• North America: U.S., Canada
• Europe: Germany, U.K., France, Italy, Spain, and Rest-of-Europe
• Asia-Pacific: China, India, Japan, Australia, South Korea, and Rest-of-Asia-Pacific
• Latin America: Brazil, Mexico, Rest-of-Latin America
• Rest-of-the-World
Market Growth Drivers
• Epigenetics Inclined by Rising Prevalence of Cancer
• Strategic Initiatives by Key Market Players
• Increasing Government Initiatives in the Field of Epigenetics
Market Challenges
• High Cost of Instruments
• Dearth of Skilled Professionals in Epigenetic Research
Market Opportunities
• Technological Advancement Toward Innovation in Epigenetics
• Expanding Epigenetic Applications in Non-Oncology Diseases
Key Companies Profiled
Thermo Fisher Scientific Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Illumina, Inc., PerkinElmer Inc., Exact Sciences Corporation, Merck KGaA, MDxHealth, Agilent Technologies, Inc., Abcam Plc, Pacific Biosciences of California, Inc., Zymo Research Corporation, Active Motif, Inc., Promega Corporation
Key Questions Answered in this Report:
• How is epigenetics revolutionizing oncology research and clinical diagnostics?
• What are the major market drivers, challenges, and opportunities in the global epigenetics market?
• What are the underlying structures resulting in the emerging trends within the global epigenetics market?
• How is the COVID-19 pandemic impacting the global epigenetics ecosystem?
• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of epigenetics targeted therapies?
• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments?
• What are the growth opportunities for the epigenetics companies in the region of their operation?
• Who are the leading players with significant offerings in the global epigenetics market?
• Which companies are anticipated to be highly disruptive in the future, and why?
Market Overview
The growth of the epigenetics market is expected to be driven by the decrease in the cost of sequencing, the global increase in the application of next-generation sequencing, and the advancement of the products. However, there are significant challenges restraining the market growth, such as the high-cost epigenetics instruments and dearth of skilled professionals in epigenetic research.
Epigenetic mechanisms are being linked to a growing number of chronic diseases and disorders, including cardiovascular diseases, autoimmune diseases, and neurodegenerative disorders, as well as environmental cues and nutrition, which have a significant impact on epigenetic processes such as DNA methylation, histone modification, and non-coding RNA.
Healthcare experts have found the epigenetics market to be one of the highest booming markets, and the global market is predicted to grow at a CAGR of 17.11% during the forecast period 2021-2031.
The epigenetics market is an emerging market with huge growth potential. Recent technological advancements are facilitating the adoption of the technology at a rapid pace. Epigenetic alterations can be maintained from cell to cell as cells divide and can be inherited through the generations.
Moreover, epigenetic changes are required for normal development and health, and they can also be responsible for some disease states. Disturbing any of the three marks that contribute to epigenetic modification can cause abnormal activation or silencing of genes. In addition, the market of epigenetics is rising due to technological advancements in products offered by the companies.
Competitive Landscape
The growth of this market can be majorly attributed to the presence of well-established guidelines regarding epigenetics, presence of established companies undertaking key business strategies, rising number of cancer cases, and increasing adoption of products based on advanced molecular technologies by the pharmaceutical and biotechnological companies, among others.
Further, increasing focus on research pertaining to the epigenetics biomarkers such as DNA, histones, and non-coding RNA is also expected to support the growth of the epigenetics market during the forecast period, 2021-2031.
The growth of other technologies, such as next-generation sequencing and whole genome sequencing, can be attributed to the increased clinical research to understand the involvement of molecular pathology in the diagnosis and prognosis of genetic disorders.
Based on region, North America holds the largest share in the market, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.
Table of Contents
1 Markets
1.1 Product Definition
1.1.1 Inclusion and Exclusion
1.2 Market Scope
1.2.1 Scope of the Study
1.2.2 Key Questions Answered in the Report
1.3 Market Overview
1.3.1 Market Definition
1.3.2 Emerging Applications of Epigenetics
1.3.2.1 DNA Methylation
1.3.2.2 Histone Modification
1.3.2.3 RNA Modification
1.3.3 Market Footprint and Growth Potential, $Million, 2020-2031
1.3.4 Disruption in Global Epigenetics Market Due to COVID-19
1.3.5 COVID-19 Affecting Supply Chain of Global Epigenetics Market
1.3.6 Interruption in Research and Clinical Development and Commercial Operation
1.3.6.1 Research and Clinical Development
1.3.6.2 Commercial Operation
1.3.7 Navigating Crisis Recovery and Looking to the Future
2 Industry Insights
2.1 Overview
2.2 Legal Requirements and Frameworks in Europe
2.3 Legal Requirements and Frameworks in Asia-Pacific
2.3.1 China
2.3.2 Japan
2.4 Reimbursement Analysis
2.5 Iceberg Analysis – Global Epigenetics Market
3 Market Dynamics
3.1 Overview
3.2 Impact Analysis
3.3 Market Drivers
3.3.1 Epigenetics Inclined by Rising Prevalence of Cancer
3.3.2 Strategic Initiatives by Key Market Players
3.3.3 Increasing Government Initiatives in the Field of Epigenetics
3.4 Market Restraints
3.4.1 High Cost of Instruments
3.4.2 Dearth of Skilled Professionals in Epigenetic Research
3.5 Market Opportunities
3.5.1 Technological Advancement Toward Innovation in Epigenetics
3.5.1.1 Epigenetics & ChIL-Alternative to ChIP-Seq
3.5.1.2 Epigenetic Time of Flight (EpiTOF)
3.5.2 Expanding Epigenetic Applications in Non-Oncology Diseases
4 Competitive Landscape
4.1 Overview
4.2 Synergistic Activities
4.3 Product Launches
4.4 Product Approvals
4.5 Mergers and Acquisitions
4.6 Other Business Activities
4.7 Market Share Analysis, 2019-2020
4.8 Growth Share Analysis (Company)
4.9 Growth Share Analysis (Technology)
5 Products, $Million, 2020-2031
5.1 Overview
5.2 Consumables
5.2.1 Kits and Assays
5.2.2 Reagents and Enzymes
5.2.3 Other Consumables
5.3 Instruments
5.4 Software
6 Mechanism
6.1 Overview
6.2 DNA Methylation
6.3 Histone Modification
6.4 RNA Modification
6.5 Other Mechanisms
7 Technology
7.1 Overview
7.2 Polymerase Chain Reaction (PCR)
7.2.1.1 Real-Time PCR (RT-PCR)
7.2.1.2 Digital PCR (dPCR)
7.2.2 Sequencing
7.2.2.1 Next-Generation Sequencing (NGS)
7.2.2.2 Traditional Sequencing (Sanger Sequencing)
7.3 Microarray
7.4 Other Technologies (MS, Flow Cytometry)
8 Application
8.1 Overview
8.2 Oncology
8.2.1 Clinical Application in Oncology
8.2.2 Translational Research Application in Oncology
8.3 Metabolic Diseases
8.3.1 Clinical Application in Metabolic Diseases
8.3.2 Translational Research Application in Metabolic Diseases
8.4 Immunology
8.4.1 Clinical Application in Immunology
8.4.2 Translational Research Application in Immunology
8.5 Cardiovascular Diseases
8.5.1 Clinical Application in Cardiovascular Diseases
8.5.2 Translational Research Application in Cardiovascular Diseases
8.6 Other Applications
8.6.1 Clinical Application in Other
8.6.2 Translational Research Application
9 End User
9.1 Overview
9.2 Pharmaceutical and Biotechnology Companies
9.3 Academic and Research Institutions
9.4 Contract Research Organizations (CROs)
9.5 Other End Users
10 Region
10.1 Overview
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 U.K.
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest-of-Europe
10.4 Asia-Pacific
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 South Korea
10.4.5 Australia
10.4.6 Rest-of-Asia-Pacific (RoAPAC)
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest-of-Latin America (RoLA)
10.6 Rest-of-the-World
11 Company Profiles
11.1 Overview
11.2 Thermo Fisher Scientific Inc.
11.2.1 Company Overview
11.2.2 Role of Thermo Fisher Scientific Inc. in the Global Epigenetics Market
11.2.3 Financials
11.2.4 Key Insights About Financial Health of the Company
11.2.5 SWOT Analysis
11.3 QIAGEN N.V.
11.3.1 Company Overview
11.3.2 Role of QIAGEN N.V. in the Global Epigenetics Market
11.3.3 Financials
11.3.4 Key Insights About Financial Health of the Company
11.3.5 SWOT Analysis
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 Company Overview
11.4.2 Role of F. Hoffmann-La Roche Ltd. in the Global Epigenetics Market
11.4.3 Financials
11.4.4 Key Insights About Financial Health of the Company
11.4.5 SWOT Analysis
11.5 Bio-Rad Laboratories, Inc.
11.5.1 Company Overview
11.5.2 Role of Bio-Rad Laboratories, Inc. in the Global Epigenetics Market
11.5.3 Financials
11.5.4 Key Insights About Financial Health of the Company
11.5.5 SWOT Analysis
11.6 Illumina, Inc.
11.6.1 Company Overview
11.6.2 Role of Illumina, Inc. in the Global Epigenetics Market
11.6.3 Financials
11.6.4 Key Insights About Financial Health of the Company
11.6.5 SWOT Analysis
11.7 PerkinElmer Inc.
11.7.1 Company Overview
11.7.2 Role of PerkinElmer Inc. in the Global Epigenetics Market
11.7.3 Financials
11.7.4 Key Insights About Financial Health of the Company
11.7.5 SWOT Analysis
11.8 Exact Sciences Corporation
11.8.1 Company Overview
11.8.2 Role of Exact Sciences Corporation in the Global Epigenetics Market
11.8.3 Financials
11.8.4 Key Insights About Financial Health of the Company
11.8.5 SWOT Analysis
11.9 Merck KGaA
11.9.1 Company Overview
11.9.2 Role of Merck KGaA in the Global Epigenetics Market
11.9.3 Financials
11.9.4 Key Insights About Financial Health of the Company
11.9.5 SWOT Analysis
11.1 MDxHealth
11.10.1 Company Overview
11.10.2 Role of MDxHealth in the Global Epigenetics Market
11.10.3 Financials
11.10.4 Key Insights About Financial Health of the Company
11.10.5 SWOT Analysis
11.11 Agilent Technologies, Inc.
11.11.1 Company Overview
11.11.2 Role of Agilent Technologies, Inc. in the Global Epigenetics Market
11.11.3 Financials
11.11.4 Key Insights About Financial Health of the Company
11.11.5 SWOT Analysis
11.12 Abcam Plc
11.12.1 Company Overview
11.12.2 Role of Abcam Plc in the Global Epigenetics Market
11.12.3 Financials
11.12.4 SWOT Analysis
11.13 Pacific Biosciences of California, Inc.
11.13.1 Company Overview
11.13.2 Role of Pacific Biosciences of California, Inc. in the Global Epigenetics Market
11.13.3 Financials
11.13.4 Key Insights About Financial Health of the Company
11.13.5 SWOT Analysis
11.14 Zymo Research Corporation
11.14.1 Company Overview
11.14.2 Role of Zymo Research Corporation in the Global Epigenetics Market
11.14.3 SWOT Analysis
11.15 Active Motif, Inc.
11.15.1 Company Overview
11.15.2 Role of Active Motif, Inc. in the Global Epigenetics Market
11.15.3 SWOT Analysis
11.16 Promega Corporation
11.16.1 Company Overview
11.16.2 Role of Promega Corporation in the Global Epigenetics Market
11.16.3 SWOT Analysis
List of Figures
Figure 1: Global Cancer Burden-2020
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Epigenetics Market
Figure 3: Global Epigenetics Market (by Product), $Million, 2020 and 2031
Figure 4: Global Epigenetics Market (by Mechanism), $Million, 2020 and 2031
Figure 5: Global Epigenetics Market (by Technology), $Million, 2020 and 2031
Figure 6: Global Epigenetics Market (by Application), $Million, 2020 and 2031
Figure 7: Global Epigenetics Market Snapshot
Figure 8: Global Epigenetics Market: Research Methodology
Figure 9: Primary Research Methodology
Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
Figure 11: Top-Down Approach (Segment-Wise Analysis)
Figure 12: Global Epigenetics Market Segmentation
Figure 13: Global Epigenetics Market, $Million, 2020-2031
Figure 14: Global Epigenetics Market: COVID-19 Impact Analysis
Figure 15: Global Cancer Burden-2020
Figure 16: Share of Key Developments and Strategies, January 2017-October 2021
Figure 17: Share of Synergistic Activities (by Company), January 2017-October 2021
Figure 18: Number of Product Launches (by Company), January 2017-October 2021
Figure 19: Share of Product Approvals (by Company), January 2017- October 2021
Figure 20: Share of Mergers and Acquisitions (by Company), January 2017– October 2021
Figure 21: Share of Other Business Activities (by Company), January 2017-October 2021
Figure 22: Market Share Analysis for Global Epigenetics Market, $Million, 2019 and 2020
Figure 23: Growth Share Analysis for Global Epigenetics Market (by Company), 2020
Figure 24: Growth Share Analysis for Global Epigenetics Market (by Technology), 2020-2031
Figure 25: Global Epigenetics Market (by Product)
Figure 26: Global Epigenetics Market (by Product), $Million, 2020 and 2031
Figure 27: Global Epigenetics Market (Consumables), $Million, 2020-2031
Figure 28: Global Epigenetics Market (Kits and Assays), $Million, 2020-2031
Figure 29: Global Epigenetics Market (Reagents and Enzymes), $Million, 2020-2031
Figure 30: Global Epigenetics Market (Other Consumables), $Million, 2020-2031
Figure 31: Global Epigenetics Market (Instruments), $Million, 2020-2031
Figure 32: Global Epigenetics Market (Software), $Million, 2020-2031
Figure 33: Global Epigenetics Market (Mechanism)
Figure 34: Global Epigenetics Market (Mechanism), $Million, 2020 and 2031
Figure 35: Global Epigenetics Market (DNA Methylation), $Million, 2020-2031
Figure 36: Global Epigenetics Market (Histone Modification), $Million, 2020-2031
Figure 37: Global Epigenetics Market (RNA Modification), $Million, 2020-2031
Figure 38: Global Epigenetics Market (Other Mechanisms), $Million, 2020-2031
Figure 39: Global Epigenetics Market (by Technology)
Figure 40: Global Epigenetics Market (by Technology), $Million, 2020 and 2031
Figure 41: Global Epigenetics Market (Polymerase Chain Reaction (PCR)), $Million, 2020-2031
Figure 42: Global Epigenetics Market (RT-PCR), $Million, 2020-2031
Figure 43: Global Epigenetics Market (dPCR), $Million, 2020-2031
Figure 44: Global Epigenetics Market (Sequencing), $Million, 2020-2031
Figure 45: Global Epigenetics Market (by Sequencing), $Million, 2020 and 2031
Figure 46: Global Epigenetics Market (NGS), $Million, 2020-2031
Figure 47: Global Epigenetics Market (Sanger Sequencing), $Million, 2020-2031
Figure 48: Global Epigenetics Market (Microarray), $Million, 2020-2031
Figure 49: Global Epigenetics Market (Other Technologies), $Million, 2020-2031
Figure 50: Global Epigenetics Market (by Application)
Figure 51: Global Epigenetics Market (by Application), $Million, 2020 and 2031
Figure 52: Global Epigenetics Market (Oncology), $Million, 2020-2031
Figure 53: Global Epigenetics Market (Clinical Application in Oncology), $Million, 2020-2031
Figure 54: Global Epigenetics Market (Translational Research Application in Oncology), $Million, 2020-2031
Figure 55: Global Epigenetics Market (Metabolic Diseases), $Million, 2020-2031
Figure 56: Global Epigenetics Market (Clinical Application in Metabolic Diseases), $Million, 2020-2031
Figure 57: Global Epigenetics Market (Translational Research Application in Metabolic Diseases), $Million, 2020-2031
Figure 58: Global Epigenetics Market (Immunology), $Million, 2020-2031
Figure 59: Global Epigenetics Market (Clinical Application in Immunology), $Million, 2020-2031
Figure 60: Global Epigenetics Market (Translational Research Application in Immunology), $Million, 2020-2031
Figure 61: Global Epigenetics Market (Cardiovascular Diseases), $Million, 2020-2031
Figure 62: Global Epigenetics Market (Clinical Application in Cardiovascular Diseases), $Million, 2020-2031
Figure 63: Global Epigenetics Market (Translational Research Application in Cardiovascular Diseases), $Million, 2020-2031
Figure 64: Global Epigenetics Market (Other Applications), $Million, 2020-2031
Figure 65: Global Epigenetics Market (Clinical Application in Other), $Million, 2020-2031
Figure 66: Global Epigenetics Market (Translational Research Application), $Million, 2020-2031
Figure 67: Global Epigenetics Market (by End User)
Figure 68: Global Epigenetics Market (by End User), $Million, 2020 and 2031
Figure 69: Global Epigenetics Market (Pharmaceutical and Biotechnology Companies), $Million, 2020-2031
Figure 70: Global Epigenetics Market (Academic and Research Institutions), $Million, 2020-2031
Figure 71: Global Epigenetics Market (Contract Research Organizations), $Million, 2020-2031
Figure 72: Global Epigenetics Market (Other End Users), $Million, 2020-2031
Figure 73: Global Epigenetics Market Snapshot (by Region), $Million, 2020-2031
Figure 74: Global Epigenetics Market (by Region), $Million, 2020-2031
Figure 75: Global Epigenetics Market (by Region), $Million, 2020 and 2031
Figure 76: North America Epigenetics Market, $Million, 2020-2031
Figure 77: North America: Market Dynamics
Figure 78: North America Epigenetics Market (by Country), $Million, 2020-2031
Figure 79: U.S. Epigenetics Market, $Million, 2020-2031
Figure 80: Canada Epigenetics Market, $Million, 2020-2031
Figure 81: Europe Epigenetics Market, $Million, 2020-2031
Figure 82: Europe: Market Dynamics
Figure 83: Europe Epigenetics Market (by Country), $Million, 2020-2031
Figure 84: Germany Epigenetics Market, $Million, 2020-2031
Figure 85: France Epigenetics Market, $Million, 2020-2031
Figure 86: U.K. Epigenetics Market, $Million, 2020-2031
Figure 87: Italy Epigenetics Market, $Million, 2020-2031
Figure 88: Spain Epigenetics Market, $Million, 2020-2031
Figure 89: Rest-of-Europe Epigenetics Market, $Million, 2020-2031
Figure 90: Asia-Pacific Epigenetics Market, $Million, 2020-2031
Figure 91: APAC: Market Dynamics
Figure 92: APAC Epigenetics Market (by Country), $Million, 2020-2031
Figure 93: China Epigenetics Market, $Million, 2020-2031
Figure 94: India Epigenetics Market, $Million, 2020-2031
Figure 95: Japan Epigenetics Market, $Million, 2020-2031
Figure 96: South Korea Epigenetics Market, $Million, 2020-2031
Figure 97: Australia Epigenetics Market, $Million, 2020-2031
Figure 98: RoAPAC Epigenetics Market, $Million, 2020-2031
Figure 99: Latin America Epigenetics Market, $Million, 2020-2031
Figure 100: Latin America: Market Dynamics
Figure 101: Global Epigenetics Market (by Country), $Million, 2020-2031
Figure 102: Brazil Epigenetics Market, $Million, 2020-2031
Figure 103: Mexico Epigenetics Market, $Million, 2020-2031
Figure 104: Rest-of-Latin America (RoLA) Epigenetics Market, $Million, 2020-2031
Figure 105: Rest-of-the-World (RoW) Epigenetics Market, $Million, 2020-2031
Figure 106: Total Number of Companies Profiled
Figure 107: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 108: Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2018-2020
Figure 109: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 110: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018-2020
Figure 111: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020
Figure 112: Thermo Fisher Scientific Inc: SWOT Analysis
Figure 113: QIAGEN N.V.: Product Portfolio
Figure 114: QIAGEN N.V.: Overall Financials, $Million, 2018-2020
Figure 115: QIAGEN N.V.: Revenue (by Segment), $Million, 2018-2020
Figure 116: QIAGEN N.V.: Revenue (by Region), $Million, 2018-2020
Figure 117: QIAGEN N.V.: R&D Expenditure, $Million, 2018-2020
Figure 118: QIAGEN N.V.: SWOT Analysis
Figure 119: F. Hoffmann-La Roche Ltd.: Product Portfolio
Figure 120: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2018-2020
Figure 121: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2018-2020
Figure 122: F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2018-2020
Figure 123: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2018-2020
Figure 124: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 125: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 126: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2018-2020
Figure 127: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 128: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 129: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 130: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 131: Illumina Inc, Product Portfolio
Figure 132: Illumina, Inc: Overall Financials, $Million, 2018-2020
Figure 133: Illumina, Inc. Revenue (by Segment), $Million, 2018-2020
Figure 134: Illumina, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 135: Illumina, Inc: R&D Expenditure, $Million, 2018-2020
Figure 136: Illumina, Inc: SWOT Analysis
Figure 137: PerkinElmer Inc.: Product Portfolio
Figure 138: PerkinElmer Inc.: Overall Financials, $Million, 2018-2020
Figure 139: PerkinElmer Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 140: PerkinElmer Inc.: Revenue (by Region), $Million, 2018-2020
Figure 141: PerkinElmer Inc.: R&D Expenditure, $Million, 2018-2020
Figure 142: PerkinElmer Inc.: SWOT Analysis
Figure 143: Exact Sciences Corporation: Service Portfolio
Figure 144: Exact Sciences Corporation: Overall Financials, $Million, 2018-2020
Figure 145: Exact Sciences Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 146: Exact Sciences Corporation: Revenue (by Region), $Million, 2018-2020
Figure 147: Exact Sciences Corporation: R&D Expenditure, $Million, 2018-2020
Figure 148: Figure 14.19: Exact Sciences Corporation: SWOT Analysis
Figure 149: Merck KGaA: Product Portfolio
Figure 150: Merck KGaA: Overall Financials, $Million, 2018-2020
Figure 151: Merck KGaA: Revenue (by Segment), $Million, 2018-2020
Figure 152: Merck KGaA: Revenue (by Region), $Million, 2018-2020
Figure 153: Merck KGaA: R&D Expenditure, $Million, 2018-2020
Figure 154: Merck KGaA: SWOT Analysis
Figure 155: MDxHealth: Service Portfolio
Figure 156: MDxHealth: Overall Financials, $Million, 2018-2020
Figure 157: MDxHealth: Revenue (by Segment), $Million, 2018-2020
Figure 158: MDxHealth: Revenue (by Region), $Million, 2018-2020
Figure 159: MDxHealth: R&D Expenditure, $Million, 2018-2020
Figure 160: MDxHealth: SWOT Analysis
Figure 161: Agilent Technologies, Inc.: Product Portfolio
Figure 162: Agilent Technologies, Inc.: Overall Financials, $Million, 2018-2020
Figure 163: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 164: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 165: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 166: Agilent Technologies, Inc.: SWOT Analysis
Figure 167: Abcam Plc: Service Portfolio
Figure 168: Abcam Plc: Overall Financials, $Million, 2018-2020
Figure 169: Abcam Plc: Revenue (by Region), $Million, 2018-2020
Figure 170: Abcam Plc: SWOT Analysis
Figure 171: Pacific Biosciences of California, Inc. Product Portfolio
Figure 172: Pacific Biosciences of California, Inc.: Overall Financials, $Million, 2018-2020
Figure 173: Pacific Biosciences of California, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 174: Pacific Biosciences of California, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 175: Pacific Biosciences of California, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 176: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 177: Zymo Research Corporation: Product Portfolio
Figure 178: Zymo Research Corporation: SWOT Analysis
Figure 179: Active Motif, Inc.: Product Portfolio
Figure 180: Active Motif, Inc.: SWOT Analysis
Figure 181: Promega Corporation.: Product Portfolio
Figure 182: Promega Corporation Inc., SWOT Analysis
List of Tables
Table 1: Key Coverage Providers for Epigenetics Tests
Table 2: Likert Scale
Table 3: Impact Analysis of Market Drivers
Table 4: Impact Analysis of Market Restraints
Table 5: Products and Prices
Table 6: Companies Providing Kits and Assays
Table 7: Companies Offering Reagents and Enzymes
Table 8: Companies Offering Other Consumables
Table 9: Companies Offering Instruments
Table 10: Companies Offering Software
Table 11: RT-PCR-Based Epigenetics Products
Table 12: dPCR-Based Epigenetics Products
Table 13: NGS-Based Epigenetics Products
